Type 2 cytokines and scleroderma interstitial lung disease.


Journal

Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 13 12 2022
accepted: 21 06 2023
medline: 2 11 2023
pubmed: 1 7 2023
entrez: 1 7 2023
Statut: ppublish

Résumé

Interstitial lung disease (ILD) is a life-threatening complication of systemic sclerosis (SSc). Type 2 (Th2) cytokines play a pivotal role in airway disease. Study aim was to evaluate serum level of Th2 interleukin (IL) and chemokine in SSc-ILD. Serum levels of IL-4, IL-5, IL-11, IL-13, IL-21, IL-31 and CXCL-13 were measured by Bio-Plex Multiplex Immunoassays in 60 SSc patients and 20 healthy controls (HC). Pulmonary function tests with diffusion lung capacity for carbon monoxide (DLco) and high resolution computed tomography (HRCT) were performed in SSc patients. ILD is defined as fibrotic changes (ground glass, reticular and honeycombing), assessed by Computer-Aided Lung Informatics for Pathology Evaluation and Ratings (CALIPER) software, affecting at least 10% of the lungs. Serum levels of Th2 cytokines were higher in SSc patients than HC. A linear correlation was observed between ground glass and IL-13 (r = 0.342, p < 0.01), IL-21 (r = 0.345, p < 0.01), IL-31 (r = 0.473, p < 0.001), IL-4 (r = 0.863, p < 0.001), IL-5 (r = 0.249, p < 0.05) and peripheral blood eosinophils (r = 0.463, p < 0.001). We found a negative correlation between DLco and IL-4 (r =  - 0.511, p < 0.001) and peripheral blood eosinophils (r =  - 0.446, p < 0.001). In the logistic regression analysis, IL-4 is associated with DLco ≤ 60% of the predicted [OR 1.039 (CI 95%: 1.015-1.064), p < 0.001], whilst mRSS [OR 1.138 (CI 95%: 1.023-1.266), p < 0.05] and IL-4 [OR 1.017 (CI 95%: 1-1.034), p < 0.05] were associated with ILD. Th2 inflammation could play a key role in early phase of SSc-ILD.

Identifiants

pubmed: 37392249
doi: 10.1007/s10238-023-01125-x
pii: 10.1007/s10238-023-01125-x
pmc: PMC10618297
doi:

Substances chimiques

Cytokines 0
Interleukin-13 0
Interleukin-4 207137-56-2
Interleukin-5 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3517-3525

Informations de copyright

© 2023. The Author(s).

Références

Rheumatology (Oxford). 2012 Sep;51(9):1540-9
pubmed: 22577083
Ann Rheum Dis. 2017 Jan;76(1):270-276
pubmed: 27621285
Nat Rev Immunol. 2015 May;15(5):271-82
pubmed: 25882242
Ann Am Thorac Soc. 2016 Nov;13(11):2045-2056
pubmed: 27560196
Am J Respir Crit Care Med. 2020 Mar 15;201(6):650-660
pubmed: 31841044
Lancet. 2017 Oct 7;390(10103):1685-1699
pubmed: 28413064
Springerplus. 2016 Aug 23;5(1):1401
pubmed: 27610320
Arthritis Rheum. 2013 Nov;65(11):2737-47
pubmed: 24122180
Ann Rheum Dis. 2021 Feb;80(2):219-227
pubmed: 32988845
N Engl J Med. 2019 Jun 27;380(26):2518-2528
pubmed: 31112379
Acad Radiol. 2017 Dec;24(12):1596-1603
pubmed: 28807589
J Rheumatol. 1997 Feb;24(2):328-32
pubmed: 9034992
Curr Opin Rheumatol. 2009 Nov;21(6):617-22
pubmed: 19633559
J Rheumatol. 1999 Oct;26(10):2159-67
pubmed: 10529133
Autoimmunity. 2018 Feb;51(1):1-9
pubmed: 29256263
Eur Respir J. 2020 May 14;55(5):
pubmed: 32079645
Arch Dermatol Res. 2020 Mar;312(2):81-92
pubmed: 31493000
Clin Rheumatol. 2020 May;39(5):1537-1542
pubmed: 31940114
Clin Exp Rheumatol. 2007 Sep-Oct;25(5):663-5
pubmed: 18078610
Lancet Respir Med. 2020 Mar;8(3):304-320
pubmed: 32113575
J Proteome Res. 2017 Aug 4;16(8):2663-2679
pubmed: 28679203
J Rheumatol. 1988 Feb;15(2):202-5
pubmed: 3361530
Ann Rheum Dis. 2010 Oct;69(10):1809-15
pubmed: 20551155
Arthritis Rheum. 1991 Apr;34(4):414-22
pubmed: 1849409
Arthritis Rheum. 2008 Apr;58(4):1165-74
pubmed: 18383361
Nat Commun. 2021 Oct 12;12(1):5947
pubmed: 34642338
J Pathol. 2008 Jan;214(2):199-210
pubmed: 18161745
Am J Respir Crit Care Med. 2002 Jun 15;165(12):1581-6
pubmed: 12070056
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
J Thorac Dis. 2021 Jul;13(7):4146-4155
pubmed: 34422344
Am J Med. 1990 May;88(5):470-6
pubmed: 2337105

Auteurs

Chiara Pellicano (C)

Department of Translational and Precision Medicine, Sapienza University of Rome, Viale Dell'Università 37, 00185, Rome, Italy.

Lorenzo Vantaggio (L)

Department of Translational and Precision Medicine, Sapienza University of Rome, Viale Dell'Università 37, 00185, Rome, Italy.

Amalia Colalillo (A)

Department of Translational and Precision Medicine, Sapienza University of Rome, Viale Dell'Università 37, 00185, Rome, Italy.

Krizia Pocino (K)

UOC of Clinical Pathology, General Hospital San Pietro Fatebenefratelli, 00189, Rome, Italy.

Valerio Basile (V)

Clinical Pathology Unit and Cancer Biobank, Department of Research and Advanced Technologies, IRCCS Regina Elena National Cancer Institute, 00144, Rome, Italy.

Mariapaola Marino (M)

Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Fondazione Policlinico A. Gemelli IRCCS, 00168, Rome, Italy.

Umberto Basile (U)

UOC Clinical Pathology DEA II Level, Hospital Santa Maria Goretti-ASL Latina, 04100, Latina, Italy.

Edoardo Rosato (E)

Department of Translational and Precision Medicine, Sapienza University of Rome, Viale Dell'Università 37, 00185, Rome, Italy. edoardo.rosato@uniroma1.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH